COOKIES USE We use necessary system cookies for the correct functioning of the website and optional Google Analytics cookies to obtain visit statistics. +info
Cookies config
Necessary
The necessary cookies are absolutely essential for the website to work properly. This category only includes cookies that guarantee basic website security and functionality. These cookies do not store any personal information.
Name
Proveedor
Propiedad
Finalidad
Caducidad
+info
_GRECAPTCHA
google.com
Own
provide antispam protection with the reCaptcha service
6 months
cc_cookie_accept
fidmag.org
Own
Usada per confirmar que l'usuari ha confirmat / refusat les cookies (i quins tipus accepta)
1 any
WEB_SESSION
fidmag.org
Own
Cookie técnica: cookie de sessió PHP. Guarda l'id de sessió d'usuari.
al acabar la sessió
Analisys
Analytical cookies are used to understand how visitors interact with the website. These cookies help to provide information on meters, the name of visitors, the percentage of bounces, the font of the traffic, etc.
Name
Proveedor
Propiedad
Finalidad
Caducidad
+info
_ga
Google Analytics
From third parties
Cookie d'anàlisi o mesurament: Identifica els usuaris i proporciona informació sobre com els usuaris troben la pàgina web i com la utilitzen per a realització d'Informes estadístics
2 anys
_gat_gtag_UA_141706552_1
Google Analytics
From third parties
Cookie d'anàlisi o mesurament: Tracking per part de google per google analytics
1 minut
_gid
Google Analytics
From third parties
Cookie d'anàlisi o mesurament: S'usa per limitar el percentatge de sol·licituds
Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs).
Bernardo M, Bioque M, Parellada M, Saiz Ruiz J, Cuesta MJ, Llerena A, Sanjuán J, Castro-Fornieles J, Arango C, Cabrera B
Limited service to collaborators of the network of Sisters Hospitalarias Centers. You will receive a message in your email with a link to download this article.
Abstract
The PEPs study is a multicenter, naturalistic, prospective, longitudinal study designed to evaluate clinical, neuropsychological, neuroimaging, biochemical, environmental and pharmacogenetic variables in a sample of nearly 350 first episode of psychosis patients and 250 healthy controls. The PEPs project was conducted in Spain from January 2009 to December 2011. This article describes the rationale for the measurement approach adopted, providing an overview of the selected clinical and functional measures. The main objectives are: a) the thorough clinical and neurocognitive characterization of a sample of first episodes of psychosis, and b) the study of the interactions between the genetic and environmental variables selected to predict clinical and brain structural outcomes, and to determine the relationship of genetic polymorphisms involved in the pharmacokinetics and pharmacodynamics, and the responses and adverse effects of treatment.